SMARCB1 and neoplasm: Using liquid biopsy as a complementary method to MRI monitoring, we confirmed an increase in tumor burden as shown by the elevated levels of cell free DNA (cfDNA) in the CSF, but also in the ctDNA as measured by the VAF of the SMARCB1 variant (Fig. 1c, d).